Clifford Chance advised Keymed Biosciences on the deal.Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the development of CM313. Investors Abingworth, Bain…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
